Skip to main content
Clinical Trials/ACTRN12616000959471
ACTRN12616000959471
Recruiting
Phase 4

A multicentre, prospective, open-label, pharmacokinetic pharmacodynamic (PKPD) study of febuxostat in patients with chronic gout.

St Vincent's Hospital0 sites120 target enrollmentJuly 21, 2016

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
St Vincent's Hospital
Enrollment
120
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 21, 2016
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
St Vincent's Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients for whom febuxostat is, or has been, clinically indicated for the treatment of chronic gout.

Exclusion Criteria

  • 1\) Any patient with a past history of febuxostat hypersensitivity.
  • 2\) Patients taking xanthine oxidoreductase substrates such as mercaptopurine/azathioprine or theophylline (no studies to substantiate the combination with febuxostat).\*
  • 3\) Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
  • 4\) Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Suspended
Phase 1
A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With SchizophreniaSchizophrenia
JPRN-jRCT2061210051Matsumaru Takehisa60
Active, not recruiting
Phase 1
A study to evaluate the effect of Levonorgestrel-Emergency Contraception Tablet on Ovulation Inhibition in groups with a BMI that ranges underweight to obeseOvulationMedDRA version: 20.0Level: PTClassification code 10036251Term: Post coital contraceptionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: LLTClassification code 10033313Term: Ovulation inhibitedSystem Organ Class: 100000004860Therapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]
EUCTR2019-001143-43-GBGedeon Richter Plc.520
Active, not recruiting
Phase 1
Study to assess the Amyloid beta draining effect of Thiethylperazine (TEP) in subjects with newly diagnosed early-to-mild dementia due to Alzheimer’s Disease in comparison to healthy volunteersewly diagnosed early-to-mild dementia due to Alzheimer's DiseaseMedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2014-000870-20-DEImmungenetics AG70
Completed
Phase 1
A Phase I, Open label, Multi-Center Clinical Pharmacological Study of nemolizumab with a Single-dose in Japanese Atopic Dermatitis Patients with moderate to severe pruritusAtopic dermatitis with pruritus who are inadequately controlled by existing therapies
JPRN-jRCT2080225290Maruho Co., Ltd.25
Active, not recruiting
Phase 1
A multicentre, open-label, repeated-dose, pharmacokinetic study of Propranolol in infants treated for proliferating infantile hemangiomas (IHs) requiring systemic therapy.Proliferating Infantile HemangiomaMedDRA version: 12.1 Level: LLT Classification code 10018814 Term: Haemangioma
EUCTR2009-018102-22-FRPIERRE FABRE DERMATOLOGIE23